



January 26, 2017

PerkinElmer Launches Vectra® Polaris™ Automated Quantitative Pathology Imaging System

New Platform Helps Research Immuno-oncologists and Pathologists Accelerate the Study of Cancer

WALTHAM, Mass. – January 26, 2017– [PerkinElmer, Inc.](#), a global leader committed to innovating for a healthier world, today announced the launch of its [Vectra® Polaris™](#) Automated Quantitative Pathology Imaging System. This new multi-modal tissue imaging system enables researchers to gain a deeper level of understanding of disease mechanisms related to new cancer immunotherapy approaches.

The Vectra Polaris system integrates high throughput, seven-color multispectral imaging with whole-slide scanning in a simplified digital pathology workflow to support the quantification and analysis of tissue sections that are stained with multiple immunohistochemical stains. This helps scientists assess biomarkers that probe deeper into the biology occurring in the immune system and cancer by detecting multiple cell types and their functional states, while also allowing researchers to determine their spatial distributions.

“From basic research to clinical research studies, scientists continue to seek advanced imaging technologies to better analyze and understand disease mechanisms,” said Jim Corbett, Executive Vice President and President, Discovery & Analytical Solutions, PerkinElmer. “The Vectra Polaris system is an innovative solution that helps further the exploration of new cancer immunotherapy approaches to help unlock the promise of precision medicine.”

The Vectra Polaris system is part of PerkinElmer's [Phenoptics™](#) workflow solution for quantitative pathology research, which enables exploration of the interaction between tumors and immune cells to obtain a deeper understanding of disease mechanisms.

“PerkinElmer's multiplex IHC platform has addressed a critical need in immuno-oncology research to reveal the cell-level biology occurring in the tumor and its microenvironment that drives disease progression and response to immunotherapy,” said Dr. Bernard A. Fox, PhD, Chief, Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center

(Oregon). “The development of the Vectra Polaris system has come at the right time, to support the transition from an exploratory research tool to a high throughput rugged high speed slide analysis research system that overlays PerkinElmer's unique multispectral technology on to a digital pathology workflow. I believe the Vectra technology will become the standard for tissue biomarker studies in immuno-oncology research and form the basis for tailoring cancer therapies of the future. ’

For more information on the Vectra Polaris system, please visit www.perkinelmer.com/vectrapolaris

For more information on PerkinElmer’s Phenoptics solutions, please visit www.perkinelmer.com/cancer-immunology

About PerkinElmer

PerkinElmer, Inc. is a global leader committed to innovating for a healthier world. The Company reported revenue of approximately \$2.3 billion in 2015, has approximately 8,000 employees serving customers in more than 150 countries, and is a component of the S&P 500 Index. Additional information is available through 1-877-PKI-NYSE or at www.perkinelmer.com.

Follow us on Twitter [@PKILifeScience](https://twitter.com/PKILifeScience).

Media Contact:

Alison Cizowski
+1 617-399-4914
perkinelmerdas@apcoworldwide.com